基于NGS的弥漫大B细胞淋巴瘤预后相关基因突变研究进展

Progress in research on prognosis-related gene mutations in diffuse large B-cell lymphoma through next generation sequencing

弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是一种高度侵袭性的恶性淋巴瘤,发病的分子机制尚未完全明确。二代测序(next generation sequencing,NGS)是一项日趋成熟的基因检测技术,近年来已广泛应用于DLBCL的基因研究。基于上述研究的靶向治疗也取得了一系列进展,使得基因突变在DLBCL中成为新的研究热点。本文就DLBCL预后相关基因突变研究进展进行综述。

Diffuse large B-cell lymphoma（DLBCL） is a highly invasive malignant lymphoma, and the molecular mechanism of its pathogenesis is not fully understood. Next generation sequencing（NGS） is an increasingly mature gene assay technology, which has been widely applied in recent years to study the genetics of DLBCL. Targeted therapy development has progressed significantly on the basis of these studies, which has made genetic mutations in DLBCL become the new research hotspot. This review summarizes the progress in research on progress-related gene mutations in DLBCL.